[DOI] [PubMed] [Google Scholar] [158].Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME, Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes, obesity & metabolism, 14 (2012) 546554
2 Context matters: 26 weeks vs 6472 weeks Cross-trial comparisons are imperfect, but for reference: Novo Nordisks oral GLP-1: 16.6% at 64 weeks Eli Lilly and Companys orforglipron: 12.4% at 72 weeks Ribupatides results came in less than half the duration, suggesting room for further upside with longer dosing
2,11 But if a patient cannot tolerate escalation and is benefiting at a low dose, I would rather keep her on a tolerable dose than lose her from treatment altogether
Tirzepatide provides a more gradual, hormonally-mediated appetite reduction that some people experience as initial fatigue before the metabolic benefits become apparent
Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., & Xu, R
